XORTX Therapeutics (TSXV:XRTX) EBIT per Share : C$-4.13 (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is XORTX Therapeutics EBIT per Share?

XORTX Therapeutics's EBIT per Share for the three months ended in Sep. 2023 was C$-0.94. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was C$-4.13.

During the past 3 years, the average EBIT per Share Growth Rate was -111.40% per year. During the past 5 years, the average EBIT per Share Growth Rate was -41.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for XORTX Therapeutics's EBIT per Share or its related term are showing as below:

TSXV:XRTX' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -111.4 Med: -19.7 Max: 18.6
Current: -111.4

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of XORTX Therapeutics was 18.60% per year. The lowest was -111.40% per year. And the median was -19.70% per year.

TSXV:XRTX's 3-Year EBIT Growth Rate is ranked worse than
97.02% of 1310 companies
in the Biotechnology industry
Industry Median: 3.45 vs TSXV:XRTX: -111.40

XORTX Therapeutics's EBIT for the three months ended in Sep. 2023 was C$-1.89 Mil.

XORTX Therapeutics EBIT per Share Historical Data

The historical data trend for XORTX Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics EBIT per Share Chart

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-1.00

-1.73

-1.51

-6.42

-4.09

XORTX Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.55	-1.35	-1.17	-0.94	-0.66

XORTX Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

XORTX Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-9.495	/	1.480
=	-6.42

XORTX Therapeutics's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.885	/	1.999
=	-0.94

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.13

XORTX Therapeutics (TSXV:XRTX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

XORTX Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (TSXV:XRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (TSXV:XRTX) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

XRTX:USA ANUA:Germany ANUA:Germany

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.